Literature DB >> 32620843

Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection.

Jonathan Virgo1, Moin Mohamed2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32620843      PMCID: PMC7333786          DOI: 10.1038/s41433-020-1069-8

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.

To the Editor:

Ophthalmic complications of COVID-19 are predicted based on prior knowledge of other coronaviruses [1]. Conjunctivitis can be the presenting sign/symptom and its presence correlates with severity [2-4]. Cotton wool spots and retinal microhaemorrhages have also been reported [5]. We report two patients who presented with a new paracentral scotoma following SARS-CoV-2 infection. Patient 1: A 37-year-old Caucasian female in week 14 of an uncomplicated pregnancy presented with a 1-day history of abrupt onset, faintly colourful, left eye paracentral scotoma. This was 35 days following the onset of a febrile illness with cough and anosmia. SARS-CoV-2 nasopharyngeal swab was not performed during the infection, but subsequently positive serology (IgG) has been confirmed. Past medical history included acephalgic visual migraine aura and right toxoplasma chorioretinitis. Examination showed normal visual acuity, no uveitis and fundoscopy was normal in the left eye. OCT changes correlated with the location of the scotoma (Fig. 1). A focal area of hyper-reflective change in the inner and outer plexiform layers with inner nuclear layer volume loss was seen consistent with paracentral acute middle maculopathy (PAMM). Bloods were normal, including ESR, CRP, lipids, glucose, ANA and anti-phospholipid antibodies. An electrocardiogram and carotid Doppler ultrasound were normal.
Fig. 1

Optical coherence tomography image from patient 1.

Focal area of hyper-reflective change in the inner and outer plexiform layers with inner nuclear layer volume loss consistent with paracentral acute middle maculopathy.

Optical coherence tomography image from patient 1.

Focal area of hyper-reflective change in the inner and outer plexiform layers with inner nuclear layer volume loss consistent with paracentral acute middle maculopathy. Patient 2: A 32-year-old Caucasian male presented with a 4-day history of abrupt onset, faintly colourful, right eye paracentral scotoma. This was 16 days following the onset of nasopharyngeal swab confirmed COVID-19. Past medical history included acephalgic visual migraine aura. Examination showed normal visual acuity, no uveitis and fundoscopy was normal. Changes on infrared reflectance (white arrow) and OCT correlated with the location of the scotoma (Fig. 2). A focal area of faint outer plexiform layer hyper-reflective change (black arrow) and disruption of the interdigitation zone (white box) were seen consistent with acute macular neuroretinopathy (AMN).
Fig. 2

Infrared reflectance and optical coherence tomography images from patient 2.

Focal area of IR change (white arrow) due to faint outer plexiform layer hyper-reflective change (black arrow) and disruption of the interdigitation zone (white box) on OCT consistent with acute macular neuroretinopathy.

Infrared reflectance and optical coherence tomography images from patient 2.

Focal area of IR change (white arrow) due to faint outer plexiform layer hyper-reflective change (black arrow) and disruption of the interdigitation zone (white box) on OCT consistent with acute macular neuroretinopathy. These patients developed PAMM and AMN soon after confirmed SARS-CoV-2 infection and possibly represent postinfectious complications. COVID-19 has been reported in association with acute limb ischaemia, stroke and the so called “paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection” [6-8]. PAMM and AMN have similar underlying pathophysiology. PAMM was first described as a variant of AMN [9], but they are now regarded as distinct conditions with overlapping features. PAMM OCT changes are seen in various retinal vascular diseases, such as retinal vein and artery occlusion. OCT angiography (OCT-A) has provided further support for a retinal vascular aetiology in PAMM and AMN [10-15]. Projection resolved OCT-A distinguishes the intermediate from the deep capillary plexus, which run either side of the inner nuclear layer. Using this technique, it has been shown that PAMM occurs in association with reduced flow in the intermediate, deep and occasionally the superficial capillary plexuses, whereas AMN occurs in association with reduced flow in the deep capillary plexus [15]. Finally, in a series of 101 AMN cases, an associated infection or febrile illness was reported in 47.5% [16]. This is the first report of PAMM/AMN following COVID-19. A larger case series is needed to determine if there is a true association.
  15 in total

Review 1.  Paracentral Acute Middle Maculopathy: What We Knew Then and What We Know Now.

Authors:  Ehsan Rahimy; Laura Kuehlewein; Srinivas R Sadda; David Sarraf
Journal:  Retina       Date:  2015-10       Impact factor: 4.256

2.  Optical Coherence Tomography Angiography of Acute Macular Neuroretinopathy and Paracentral Acute Middle Maculopathy.

Authors:  Paula E Pecen; Adiel G Smith; Justis P Ehlers
Journal:  JAMA Ophthalmol       Date:  2015-12       Impact factor: 7.389

3.  Projection-Resolved OCT Angiography of Microvascular Changes in Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy.

Authors:  Sally Chu; Peter L Nesper; Brian T Soetikno; Sophie J Bakri; Amani A Fawzi
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-06-01       Impact factor: 4.799

4.  Microvascular change in acute macular neuroretinopathy by using optical coherence tomography angiography.

Authors:  Yen-Chih Chen; San-Ni Chen
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

5.  Retinal findings in patients with COVID-19.

Authors:  Paula M Marinho; Allexya A A Marcos; André C Romano; Heloisa Nascimento; Rubens Belfort
Journal:  Lancet       Date:  2020-05-12       Impact factor: 79.321

6.  Acute limb ischemia in patients with COVID-19 pneumonia.

Authors:  Raffaello Bellosta; Luca Luzzani; Giuseppe Natalini; Matteo Alberto Pegorer; Luca Attisani; Luisa Giuseppina Cossu; Camillo Ferrandina; Alessandro Fossati; Elena Conti; Ruth L Bush; Gabriele Piffaretti
Journal:  J Vasc Surg       Date:  2020-04-29       Impact factor: 4.268

Review 7.  Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals.

Authors:  Ivan Seah; Rupesh Agrawal
Journal:  Ocul Immunol Inflamm       Date:  2020-03-16       Impact factor: 3.070

8.  Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China.

Authors:  Ping Wu; Fang Duan; Chunhua Luo; Qiang Liu; Xingguang Qu; Liang Liang; Kaili Wu
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

9.  Conjunctivitis can be the only presenting sign and symptom of COVID-19.

Authors:  Sergio Zaccaria Scalinci; Edoardo Trovato Battagliola
Journal:  IDCases       Date:  2020-04-24

10.  Conjunctivitis and COVID-19: A meta-analysis.

Authors:  Lorenzo Loffredo; Fernanda Pacella; Elena Pacella; Giulia Tiscione; Alessandra Oliva; Francesco Violi
Journal:  J Med Virol       Date:  2020-05-22       Impact factor: 20.693

View more
  41 in total

1.  Branch Retinal Vein Occlusion in a COVID-19 Positive Patient.

Authors:  Sarah Madison Duff; Matthew Wilde; Gibran Khurshid
Journal:  Cureus       Date:  2021-02-27

2.  Neurocognitive Profile of the Post-COVID Condition in Adults in Catalonia-A Mixed Method Prospective Cohort and Nested Case-Control Study: Study Protocol.

Authors:  Rosalia Dacosta-Aguayo; Noemí Lamonja-Vicente; Carla Chacón; Lucia Amalía Carrasco-Ribelles; Pilar Montero-Alia; Anna Costa-Garrido; Rosa García-Sierra; Victor M López-Lifante; Eduard Moreno-Gabriel; Marta Massanella; Josep Puig; Jose A Muñoz-Moreno; Lourdes Mateu; Anna Prats; Carmina Rodríguez; Maria Mataró; Julia G Prado; Eva Martínez-Cáceres; Concepción Violán; Pere Torán-Monserrat
Journal:  Vaccines (Basel)       Date:  2022-05-26

3.  Fulminant fungal endogenous endophthalmitis following SARS-CoV-2 infection: A case report.

Authors:  Mukesh Jain; Anand Singh Brar; Suryasnata Rath; Anup Kelgaokar; Himansu Sekhar Behera
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

4.  Coronavirus-19-Associated Retinopathy.

Authors:  Christopher D Conrady; Lisa J Faia; Kevin S Gregg; Rajesh C Rao
Journal:  Ocul Immunol Inflamm       Date:  2021-04-15       Impact factor: 3.070

Review 5.  Pre-existing diabetic retinopathy as a prognostic factor for COVID-19 outcomes amongst people with diabetes: A systematic review.

Authors:  Isabel Boden; Miguel O Bernabeu; Baljean Dhillon; David A Dorward; Ian MacCormick; Roly Megaw; Claire Tochel
Journal:  Diabetes Res Clin Pract       Date:  2022-04-05       Impact factor: 8.180

6.  Acute macular neuroretinopathy in a patient with acute myeloid leukemia and deceased by COVID-19: a case report.

Authors:  Ghodsieh Zamani; Sajjad Ataei Azimi; Ali Aminizadeh; Elham Shams Abadi; Mostafa Kamandi; Hasan Mortazi; Somayeh Shariat; Mojtaba Abrishami
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-01-08

7.  Central retinal vein occlusion in a young healthy COVID-19 patient: A case report.

Authors:  Tal Yahalomi; Joseph Pikkel; Roee Arnon; Yuval Pessach
Journal:  Am J Ophthalmol Case Rep       Date:  2020-11-16

8.  [Flickering scotoma after COVID vaccination : A further possible side effect of vaccination?]

Authors:  K Gabka; S Groselli; M Ulbig
Journal:  Ophthalmologe       Date:  2021-06-21       Impact factor: 1.059

Review 9.  Ocular manifestations of SARS-CoV-2: Literature review.

Authors:  F Pérez-Bartolomé; J Sánchez-Quirós
Journal:  Arch Soc Esp Oftalmol (Engl Ed)       Date:  2020-08-08

10.  COVID-19: more than a respiratory virus, an optical coherence tomography study.

Authors:  Esra Dag Seker; Inci Elif Erbahceci Timur
Journal:  Int Ophthalmol       Date:  2021-07-27       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.